共 50 条
- [21] EV-103 study: A phase 1b dose-escalation and doseexpansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)Hoimes, Christopher J.Petrylak, Daniel PeterFlaig, Thomas W.Carret, Anne-SophieMelhem-Bertrandt, AmalRosenberg, Jonathan E.
- [22] MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II studyANNALS OF ONCOLOGY, 2024, 35 : S1151 - S1151Cui, C.Zhou, L.Yang, Y.Qu, W.Sheng, X.Chi, Z.Si, L.Mao, L.Lian, B.Wang, X.Yan, X.Li, S.Li, C.Wei, X.Li, J.Duan, R.Xu, H.Zhou, A.Guo, J.
- [23] A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029CANCER, 2023, 129 (02) : 264 - 271Salous, TareqShukla, Nikhil A. A.Althouse, Sandra K. K.Perkins, Susan M. M.Furqan, MuhammadLeal, TicianaTraynor, Anne M. M.Feldman, Lawrence E. E.Hanna, Nasser H. H.Durm, Greg A. A.
- [24] Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study (vol 10, 3538, 2021)TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (10) : 2146 - 2147Rounis, KonstantinosMakrakis, DimitriosTsigkas, Alexandros-PantelisGeorgiou, AlexandraGalanakis, NikolaosPapadaki, CharaMonastirioti, AlexiaVamvakas, LambrosKalbakis, KonstantinosVardakis, NikolaosKontogianni, MeropiGioulbasanis, IoannisMavroudis, DimitriosAgelaki, Sofia
- [25] Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapyTHORACIC CANCER, 2023, 14 (08) : 773 - 778Liu, JiaChen, MinjiangGao, XiaoxingLiu, XiaoyanZhao, JingPan, RuiliZhong, WeiXu, YanWang, Mengzhao
- [26] Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC)JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)Siefker-Radtke, Arlene O.Necchi, AndreaRosenbaum, EliCuline, StephaneBurgess, Earle FrederickO'Donnell, Peter H.Tagawa, Scott T.Zakharia, YousefOHagan, AnneAvadhani, Anjali NarayanZhong, BobSantiago-Walker, Ademi E.Roccia, TitoLoriot, Yohann
- [27] Folgelinientherapie mit Cabozantinib bei lokal fortgeschrittenem oder metastasiertem Urothelkarzinom nach ImmuntherapieversagenCabozantinib bei Patienten mit lokal fortgeschrittenem oder metastasiertem Urothelzellkarzinom mit progredientem Verlauf nach Vortherapie mit einer Kombination aus platinbasierter Chemotherapie und PD-1/PD-L1-Inhibitoren oder Monotherapie mit PD-1/PD-L1-Inhibitoren (CabUC-Trial) – AB 66/18 der AUOFurther-line therapy with cabozantinib in locally advanced or metastasized urothelial carcinoma following failure of immunotherapyCabozantinib in patients with locally advanced or metastasized urothelial carcinoma with progression after pretreatment with a combination of platinum-based chemotherapy and PD-1/PD-L1 inhibitors or monotherapy with PD-1/PD-L1 inhibitors (CabUC trial)—AB 66/18 of the AUOForum, 2021, 36 (2) : 172 - 173H. RexerG. BartschC.-H. Ohlmann
- [28] Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Milowsky, Matthew I.O'Donnell, Peter H.Hoimes, Christopher J.Petrylak, Daniel P.Flaig, Thomas W.Moon, Helen H.Friedlander, Terence W.Mar, NataliyaMcKay, Rana R.Srinivas, SandyGravis, GwenaelleRamamurthy, ChethanBupathi, ManojkumarBracarda, SergioWright, PhoebeCarret, Anne-SophieYu, YaoMatsuda, TaraKataria, Ritesh S.Rosenberg, Jonathan E.
- [29] First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)Ren, ShengxiangWang, XichengHan, Bao-HuiPan, YueyinZhao, JunCheng, YufengHu, ShengLiu, TianshuLi, YalunCheng, YingFeng, JifengYi, ShanyongGu, ShanzhiGao, SheganLuo, YongzhongLiu, YingLiu, CaigangDuan, HuijieWang, ShuniYang, XinfengFan, JiaZhou, Caicun
- [30] HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO ADVANCED DRY AGE-RELATED MACULAR DEGENERATION: RESULTS FROM A PHASE 1/2A CLINICAL TRIAL OF CNTO 2476VALUE IN HEALTH, 2016, 19 (03) : A127 - A127Pierson, R. F.Orr, S.Bogert, J.Malone, T.Crosby, R. D.Mathias, S. D.Chang, T. S.